EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of Anti-BNLF2b Antibody and Epstein–Barr Virus Biomarkers for the Diagnosis of Nasopharyngeal Carcinoma: A Retrospective Study

Hongyu Deng, Qinglin Liu, Haoming Shen, Ping Xiao iD

Technology in Cancer Research & Treatment · 2026

DOI: 10.1177/15330338251412015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2026. Verfasst von Hongyu Deng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Key Laboratory of Oncotarget Gene, The Afffliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital…. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Nasopharyngeal Carcinoma, Biomarkers, Tumor, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Hunan Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To validate the diagnostic performance of anti-BNLF2b antibody for detecting nasopharyngeal carcinoma (NPC) compared with healthy controls (HC).

Methods

We conducted a retrospective study including 220 patients with NPC, 61 with tongue cancer (TC), and 88 HC patients. We collected demographic and clinical data, including anti-BNLF2b antibody, EBV DNA, VCA-IgA, EBNA1-IgA, and Rta-IgG. Propensity score matching (PSM) was used to balance baseline characteristics between NPC and comparison groups. Associations between biomarkers and NPC diagnosis were examined using logistic regression. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis.

Results

After PSM, 88 patients with NPC were matched to 88 HC with balanced baseline characteristics. Anti-BNLF2b antibody levels were significantly higher in NPC and remained independently associated with NPC diagnosis. For NPC versus HC, anti-BNLF2b antibody showed excellent discrimination (AUC = 0.990; sensitivity 98.9%; specificity 92.0% at a cut-off of 0.210), exceeding the performance of the EBV dual antibody risk probability (AUC: 0.872; P < 0.001). In addition, patients with NPC had higher anti-BNLF2b antibody levels and other EBV-related markers than those with TC.

Conclusion

In this retrospective study, anti-BNLF2b antibody demonstrated excellent discrimination for NPC. It may serve as a complementary serologic marker, pending external validation and prospective assessment of clinically optimized cutoffs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 4, HumanNasopharyngeal CarcinomaBiomarkers, TumorNasopharyngeal NeoplasmsEpstein-Barr Virus InfectionsAntibodies, ViralHumansFemaleMaleRetrospective StudiesMiddle AgedAdultROC CurveAged

Stichwörter der Autor:innen

Epstein-Barr virusanti-BNLF2b antibodybiomarkernasopharyngeal carcinomasurveillance

Substanzen

Biomarkers, TumorAntibodies, Viral

Autor:innen und Institutionen

  • Hunan Key Laboratory of Oncotarget Gene, The Afffliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.

ORCID-Profile: Ping Xiao

Förderung

  • Natural Science Foundation of Hunan Province of China

Zitieren

APA

Deng, H., Liu, Q., Shen, H., & Xiao, P. (2026). Evaluation of Anti-BNLF2b Antibody and Epstein–Barr Virus Biomarkers for the Diagnosis of Nasopharyngeal Carcinoma: A Retrospective Study. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338251412015

Vancouver

Deng H, Liu Q, Shen H, Xiao P. Evaluation of Anti-BNLF2b Antibody and Epstein–Barr Virus Biomarkers for the Diagnosis of Nasopharyngeal Carcinoma: A Retrospective Study. Technology in Cancer Research & Treatment. 2026. doi:10.1177/15330338251412015

BibTeX
@article{Deng2026,
  author = {Deng, Hongyu and Liu, Qinglin and Shen, Haoming and Xiao, Ping},
  title = {Evaluation of Anti-BNLF2b Antibody and Epstein–Barr Virus Biomarkers for the Diagnosis of Nasopharyngeal Carcinoma: A Retrospective Study},
  journal = {Technology in Cancer Research & Treatment},
  year = {2026},
  doi = {10.1177/15330338251412015}
}
Kostenlos starten →